Meeting
2015 ASCO Annual Meeting
Phase I study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in Japanese patients with advanced solid tumors.
Authors
Haruo Iguchi
Clinical Research Institute, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
Haruo Iguchi , Naoyuki Nogami , Toshiyuki Kozuki , Toshihiko Matsumoto , Kenji Tamura , Noboru Yamamoto , Akihiko Shimomura , Yuji Hoshino , Yoshiko Michibata , Masahiro Nii , Yutaka Fujiwara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immunotherapy and Biologic Therapy
Clinical Trial Registration Number
NCT01938612
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3039)
DOI
10.1200/jco.2015.33.15_suppl.3039
Abstract #
3039
Poster Bd #
365
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase I study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors.
First Author: Patrick Alexander Ott
Poster
2015 ASCO Annual Meeting
Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies.
First Author: Omid Hamid
Poster
2015 ASCO Annual Meeting
Phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in myelodysplastic syndrome (MDS) after treatment with hypomethylating agents.
First Author: Guillermo Garcia-Manero
Poster
2015 ASCO Annual Meeting
Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).
First Author: Naiyer A. Rizvi